WHO authorizes emergency use of Novavax’s updated COVID vaccine – CNBCTV18
The single-target vaccine is aimed at the XBB.1.5 Omicron subvariant of the coronavirus, which was dominant in the U.S. for much of this year but has since been overtaken by other variants as the virus evolves.
The Maryland-based biotech’s updated COVID shot, which was authorized in the U.S. in October, uses a more traditional protein-based technology than the mRNA-based vaccines by rivals Pfizer and Moderna.